Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2.

Vibeke StrandFilip Van den BoschRoberto RanzaYing-Ying LeungEdit DrescherPatrick ZuegerChristopher D SafforeApinya LertratanakulRalph LippePeter Nash

Published in: Rheumatology and therapy (2021)

Upadacitinib provides rapid, clinically meaningful, and sustained improvements in PROs reported by bDMARD-IR PsA patients. SELECT-PsA 2 ClinicalTrials.gov number, NCT03104374.

Keyphrases

patient reported outcomes
prostate cancer
rheumatoid arthritis
end stage renal disease
radical prostatectomy
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
systemic lupus erythematosus
quantum dots
sensitive detection
patient reported